脾脏在肝癌合并肝硬化中的临床价值

doi:10.16139/j.1007-9610.2023.04.018

摘要/Abstract

摘要：

脾脏作为人体最大的淋巴器官，可通过门静脉系统影响肝脏的免疫微环境。肝癌病人往往因为肝硬化和门静脉高压而出现脾功能亢进（脾亢）和脾肿大。脾脏功能失调不仅诱发肝脏纤维化，还改变肝脏的免疫调节，加速肝硬化和抑制肝脏再生能力，且使肝内微环境和免疫系统趋向“促肿瘤生成”与“肿瘤耐受”的状态。脾脏切除术已被证实在术后短期内可改善肝癌病人的一般状态、肝功能，甚至免疫力。因此，脾脏切除术可能提高肝癌病人术后抗癌治疗的耐受性。但对于合并门静脉高压和脾亢的肝癌病人选择进行肝脾联合切除是否存在远期效益或提高生存率仍有争议。

关键词: 肝癌, 脾脏, 门静脉高压, 肝硬化

Abstract:

The spleen is the largest lymphoid organ that can affect the immunological microenvironment in the liver via the portal system. Patients with liver cancer, often develop hypersplenism and splenomegaly from underlying cirrhosis and portal hypertension. The malfunction of the spleen not only induces hepatic fibrogenesis, but also changes the immune responses in the liver, so that liver cirrhosis accelerates while liver regeneration subdues. As a result, the hepatic microenvironment and the rest of the immune system reach a “tumor progressing” or “tumor tolerant” state. Splenectomy has been shown to improve immune responses, liver function and general condition in patients with liver cancer. Hence, splenectomy may possibly improve the tolerance in live cancer patients for other anticancer treatments. However, the long-term benefits and effects on the overall survival of concomitant hepatectomy and splenectomy for liver cancer patients with portal hypertension and hypersplenism still remain controversial.

Key words: Liver cancer, Spleen, Portal hypertension, Cirrhosis

中图分类号:

Chang Jessica, 陈旭晓, 陈拥军. 脾脏在肝癌合并肝硬化中的临床价值[J]. 外科理论与实践, 2023, 28(04): 394-398.

CHANG Jessica, CHEN Xuxiao, CHEN Yongjun. Role of the spleen in patients with liver cancer and cirrhosis[J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 394-398.

参考文献 37

[1]	SHI X B, FENG J K, WANG J H, et al. Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta-analysis[J]. Ann Transl Med, 2021, 9(8):641. doi: 10.21037/atm URL
[2]	LI L, DUAN M, CHEN W, et al. The spleen in liver cirrhosis: revisiting an old enemy with novel targets[J]. J Transl Med, 2017, 15(1):111. doi: 10.1186/s12967-017-1214-8 pmid: 28535799
[3]	张谞丰, 刘阳, 李建辉, 等. 脾切除对病毒性肝炎肝硬化合并门静脉高压症患者肝癌发生影响的多中心队列研究[J]. 中华外科杂志, 2021, 59(10):821-828.
	ZHANG X F, LIU Y, LI J H, et al. Effect of splenectomy on the risk of hepatocellular carcinoma development among patients with liver cirrhosis and portal hypertension: a multi-institutional cohort study[J]. Chin J Surg, 2021, 59(10):821-828.
[4]	朱维刚. 肝脾联合切除对肝癌伴肝硬化脾功能亢进患者肝功能和免疫指标的影响[J]. 中国实验诊断学, 2015,(1):108-110.
	ZHU W G. The effect of combined liver and spleen resection on liver function and immune indicators in patients with liver cancer accompanied by cirrhosis and hypersplenism[J]. Chin J Lab Diagn, 2015,(1):108-110.
[5]	ELCHANINOV A V, FATKHUDINOV T K, VISHNYAKOVA P A, et al. Molecular mechanisms of splenectomy-induced hepatocyte proliferation[J]. PLoS One, 2020, 15(6):e0233767. doi: 10.1371/journal.pone.0233767 URL
[6]	XIE X L, LIU X, OU J. Is synchronous hepatectomy and splenectomy superior to hepatectomy alone for selected patients with hepatocellular carcinoma and clinically significant portal hypertension?[J]. J Surg Oncol, 2019, 120(2):316-317. doi: 10.1002/jso.v120.2 URL
[7]	LEWIS S M, WILLIAMS A, EISENBARTH S C. Structure and function of the immune system in the spleen[J]. Sci Immunol, 2019, 4(33):eaau6085. doi: 10.1126/sciimmunol.aau6085 URL
[8]	TURCO L, GARCIA-TSAO G. Portal hypertension: pathogenesis and diagnosis[J]. Clin Liver Dis, 2019, 23(4):573-587. doi: S1089-3261(19)30050-9 pmid: 31563212
[9]	MENDES F D, SUZUKI A, SANDERSON S O, et al. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2012, 10(9):1028-1033.e2. doi: 10.1016/j.cgh.2012.05.008 URL
[10]	SWIRSKI F K, NAHRENDORF M, ETZRODT M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites[J]. Science, 2009, 325(5940):612-616. doi: 10.1126/science.1175202 pmid: 19644120
[11]	INDIRAN V, VINOD SINGH N, RAMACHANDRA PRASAD T, et al. Does coronal oblique length of spleen on CT reflect splenic index?[J]. Abdom Radiol(NY), 2017, 42(5):1444-1448.
[12]	TARANTINO G, SCALERA A, FINELLI C. Liver-spleen axis: intersection between immunity, infections and metabolism[J]. World J Gastroenterol, 2013, 19(23):3534-3542. doi: 10.3748/wjg.v19.i23.3534 URL
[13]	ZHOU W C, ZHANG Q B, QIAO L. Pathogenesis of liver cirrhosis[J]. World J Gastroenterol, 2014, 20(23):7312-7324. doi: 10.3748/wjg.v20.i23.7312 URL
[14]	TANABE K, TAURA K, KOYAMA Y, et al. Migration of splenic lymphocytes promotes liver fibrosis through modification of T helper cytokine balance in mice[J]. J Gas-troenterol, 2015, 50(10):1054-1068.
[15]	ROMANO A, HOU X, SERTORIO M, et al. FOXP3+ regulatory T cells in hepatic fibrosis and splenomegaly caused by schistosoma japonicum: the spleen may be a major source of tregs in subjects with splenomegaly[J]. PLoS Negl Trop Dis, 2016, 10(1):e0004306. doi: 10.1371/journal.pntd.0004306 URL
[16]	WANG Y, GUO X, JIAO G, et al. Splenectomy promotes macrophage polarization in a mouse model of concanavalin A- (ConA-) induced liver fibrosis[J]. Biomed Res Int, 2019, 2019:5756189.
[17]	YADA A, IIMURO Y, UYAMA N, et al. Splenectomy attenuates murine liver fibrosis with hypersplenism stimulating hepatic accumulation of Ly-6C(lo) macrophages[J]. J Hepatol, 2015, 63(4):905-916. doi: 10.1016/j.jhep.2015.05.010 pmid: 26022691
[18]	KITAMURA T, QIAN B-Z, POLLARD J W. Immune cell promotion of metastasis[J]. Nat Rev Immunol, 2015, 15(2):73-86. doi: 10.1038/nri3789 pmid: 25614318
[19]	SEHGAL R, KAUR N, RAMAKRISHNA G, et al. Immune surveillance by myeloid-derived suppressor cells in liver diseases[J]. Dig Dis, 2022, 40(3):301-312. doi: 10.1159/000517459 URL
[20]	WU C, NING H, LIU M, et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis[J]. J Clin Invest, 2018, 128(8):3425-3438. doi: 10.1172/JCI97973 pmid: 29771686
[21]	UGEL S, PERANZONI E, DESANTIS G, et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen[J]. Cell Rep, 2012, 2(3):628-639. doi: 10.1016/j.celrep.2012.08.006 pmid: 22959433
[22]	LEE S C, JEONG H J, CHOI B-J, et al. Role of the spleen in liver regeneration in relation to transforming growth factor-β1 and hepatocyte growth factor[J]. J Surg Res, 2015, 196(2):270-277. doi: 10.1016/j.jss.2015.02.025 pmid: 25862490
[23]	ISHIKAWA J, TAKEO M, IWADATE A, et al. Mechanical homeostasis of liver sinusoid is involved in the initiation and termination of liver regeneration[J]. Commun Biol, 2021, 4(1):409. doi: 10.1038/s42003-021-01936-2 pmid: 33828226
[24]	TROISI R, CAMMU G, MILITERNO G, et al. Modulation of portal graft inflow: a necessity in adult living-donor liver transplantation?[J]. Ann Surg, 2003, 237(3):429-436. pmid: 12616129
[25]	GLANEMANN M, EIPEL C, NUSSLER A K, et al. Hyperperfusion syndrome in small-for-size livers[J]. Eur Surg Res, 2005, 37(6):335-341. doi: 10.1159/000090333 pmid: 16465057
[26]	EIPEL C, ABSHAGEN K, RITTER J, et al. Splenectomy improves survival by increasing arterial blood supply in a rat model of reduced-size liver[J]. Transpl Int, 2010, 23(10):998-1007. doi: 10.1111/j.1432-2277.2010.01079.x pmid: 20302595
[27]	European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236. doi: S0168-8278(18)30215-0 pmid: 29628281
[28]	中华医学会外科学分会脾及门静脉高压外科学组. 门静脉高压合并肝癌的临床诊疗专家共识(2022版)[J]. 中华外科杂志, 2022, 60(4),310-320.
	Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Expert consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma (2022)[J]. Chin J Surg, 2022, 60(4):310-320.
[29]	ZHOU C, HUANG Y, SHU C, et al. Splenectomy before hepatectomy for patients with hepatocellular carcinoma and hypersplenism: a retrospective study[J]. Medicine(Baltimore), 2021, 100(4):e24326.
[30]	KULIK L, EL-SERAG H B. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 156(2):477-491.e1. doi: S0016-5085(18)35165-5 pmid: 30367835
[31]	FAITOT F, ALLARD M A, PITTAU G, et al. Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation[J]. Hepatology, 2015, 62(1):179-187. doi: 10.1002/hep.27864 pmid: 25914217
[32]	TEUBEN M P J, HOLLMAN A, BLOKHUIS T, et al. Splenectomy is associated with altered leukocyte kinetics after severe trauma[J]. Eur J Med Res, 2021, 26(1):26. doi: 10.1186/s40001-021-00497-8 pmid: 33722293
[33]	PEI Y, CHAI S, ZHANG Y, et al. Benefits of splenectomy and curative treatments for patients with hepatocellular carcinoma and portal hypertension: a retrospective study[J]. J Gastrointest Surg, 2019, 23(11):2151-2162. doi: 10.1007/s11605-018-3981-9 pmid: 30511133
[34]	KONG L, LI M, LI L, et al. Splenectomy before adult liver transplantation: a retrospective study[J]. BMC Surg, 2017, 17(1):44. doi: 10.1186/s12893-017-0243-9 pmid: 28427382
[35]	KAWANAKA H, AKAHOSHI T, KINJO N, et al. Laparoscopic splenectomy with technical standardization and selection criteria for standard or hand-assisted approach in 390 patients with liver cirrhosis and portal hypertension[J]. J Am Coll Surg, 2015, 221(2):354-366. doi: 10.1016/j.jamcollsurg.2015.04.011 URL
[36]	LI W, SHEN S Q, WU S M, et al. Simultaneous hepatectomy and splenectomy versus hepatectomy alone for hepatocellular carcinoma complicated by hypersplenism: a meta-analysis[J]. Onco Targets Ther, 2015, 8:2129-2137.
[37]	SINWAR P D. Overwhelming post splenectomy infection syndrome-review study[J]. Int J Surg, 2014, 12(12):1314-1316. doi: 10.1016/j.ijsu.2014.11.005 URL